Ozebrut Cream contains Ozenoxacin 1% w/w, a topical non-fluorinated quinolone antibiotic indicated for the treatment of impetigo and other superficial bacterial skin infections caused by susceptible strains of Staphylococcus aureus and Streptococcus pyogenes. Ozenoxacin exhibits bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, and repair. The cream formulation allows for targeted delivery to the affected area, minimizing systemic absorption and reducing the risk of systemic side effects. Ozebrut Cream is typically applied twice daily to the affected skin areas for a duration of 5 days, or as directed by a healthcare professional. Clinical studies have demonstrated its efficacy in reducing lesion size, bacterial load, and associated symptoms such as erythema and pruritus. The product is generally well tolerated; however, local adverse reactions such as mild burning, itching, or erythema may occur. Ozebrut Cream should be used with caution in patients with known hypersensitivity to quinolones or any of the excipients. It is contraindicated for use on deep or extensive skin infections, mucous membranes, or in patients with a history of photosensitivity reactions. Proper hygiene and adherence to treatment duration are essential to prevent resistance development and ensure optimal therapeutic outcomes.